Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sarepta Therapeutics Inc    SRPT

SAREPTA THERAPEUTICS INC (SRPT)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Sarepta Therapeutics Inc : SRPT, FB, CRUS and OMER added to NASDAQ Active Stock Watch List at GSR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/24/2013 | 03:05pm CEST

New York, NY - (ACCESSWIRE) - 09/24/2013 - Growing Stock Report initiates its NASDAQ Active Stock Watch List adding Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Facebook, Inc. (NASDAQ:FB), Cirrus Logic Inc. (NASDAQ:CRUS), and Omeros Corporation (NASDAQ:OMER)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) a biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases closed up in its previous session (+10.79%) on 6,581,320 shares traded after Sarepta was upgraded to Overweight from Neutral at Piper Jaffray. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is currently up (+251.61%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=SRPT&SubId=AW

Facebook, Inc. (NASDAQ:FB) operates as a social networking company worldwide closed down in its previous session (-0.63%) on 75,274,915 shares traded after Facebook Quietly Rolls Out Its Mobile Payments Autofill Product, AllThingsD Reported. Facebook, Inc. (NASDAQ:FB) is currently down (-2.75%) from its recent 52-week high, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Facebook, Inc. (NASDAQ:FB)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=FB&SubId=AW

Cirrus Logic Inc. (NASDAQ:CRUS) a fabless semiconductor company that develops analog and mixed-signal integrated circuits for a range of consumer and industrial markets closed up in its previous session (+5.41%) on 6,219,309 shares traded after CIRRUS LOGIC INC Filed SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year. Cirrus Logic Inc. (NASDAQ:CRUS) is currently up (+46.96%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Cirrus Logic Inc. (NASDAQ:CRUS)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=CRUS&SubId=AW

Omeros Corporation (NASDAQ:OMER) a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system closed up in its previous session (+28.21%) on 8,095,031 shares traded after Omeros has been Chosen to Present at NewsMakers in the Biotech Industry 2013 Conference on Friday, September 27, 2013. Omeros Corporation (NASDAQ:OMER) is currently up (+167.95%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Omeros Corporation (NASDAQ:OMER)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=OMER&SubId=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
[email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SAREPTA THERAPEUTICS INC
06/22SAREPTA THERAPEUTICS : says no to right to try for its DMD therapies
AQ
06/22SAREPTA THERAPEUTICS : Sareptas Duchenne gene therapy shows promise in small stu..
AQ
06/21SAREPTA THERAPEUTICS : shares surge after gene therapy leads to microdystrophin ..
AQ
06/20SAREPTA THERAPEUTICS : With tantalizing early results, Sareptas gene therapy for..
AQ
06/20TODAY'S RESEARCH REPORTS ON STOCKS T : Sarepta Therapeutics and Caladrius Biosci..
AC
06/20SAREPTA THERAPEUTICS : hits high on Phase I/IIa DMD readout
AQ
06/19SAREPTA THERAPEUTICS, INC. (NASDAQ : SRPT) Files An 8-K Regulation FD Disclosure
AQ
06/19SAREPTA THERAPEUTICS : Announces that at its First R&D Day, Jerry Mendell, M.D. ..
PU
06/19SAREPTA THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and ..
AQ
06/19SAREPTA THERAPEUTICS : Announces that at its First R&D Day, Jerry Mendell, M.D. ..
AQ
More news
News from SeekingAlpha
06/21YOUR DAILY PHARMA SCOOP : Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta S.. 
06/21SAREPTA THERAPEUTICS : Chasing The Good News 
06/20Gene therapy players in the green 
06/20Sarepta Therapeutics (SRPT) R&D Day 2018 - Slideshow 
06/20A Short Case For A Longer Term! 
Financials ($)
Sales 2018 300 M
EBIT 2018 -131 M
Net income 2018 -135 M
Finance 2018 390 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 29,4x
EV / Sales 2019 20,0x
Capitalization 9 196 M
Chart SAREPTA THERAPEUTICS INC
Duration : Period :
Sarepta Therapeutics Inc Technical Analysis Chart | SRPT | US8036071004 | 4-Traders
Technical analysis trends SAREPTA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 172 $
Spread / Average Target 23%
EPS Revisions
Managers
NameTitle
Douglas S. Ingram President, Chief Executive Officer & Director
M. Kathleen Behrens Chairman
Sandesh Mahatme Executive VP, Chief Financial & Business Officer
Guriqbal S. Basi Chief Scientific Officer
Gilmore O’Neill Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
SAREPTA THERAPEUTICS INC152.21%9 196
GILEAD SCIENCES-0.80%92 410
VERTEX PHARMACEUTICALS6.23%40 566
REGENERON PHARMACEUTICALS-11.70%35 172
GENMAB-3.32%9 557
NEUROCRINE BIOSCIENCES, INC.31.19%9 151